Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)

A Multi-center, Randomized, Controlled, Partially Blinded Study to Assess the Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of Nicotine Pouch 2.0 (NP2), 4mg and 6mg, Compared to Nicotine Lozenge 4mg and Nicotine Gum 4mg in Adult Cigarette Smokers

This is a multi-center, randomized, controlled, partially blinded study to assess the pharmacokinetics and comparative bioavailability of nicotine from two variants of NP2 (4 and 6 mg) in comparison with Loz-4mg and Gum-4mg in adult cigarette smokers. The subjects will be blinded to the randomized sequence and will be blinded to the variants of NP2 they will receive. The study will be conducted with 4 periods and 4 sequences in a Williams design (crossover).

Study Overview

• Status: Active, not recruiting
• Conditions: Tobacco Use
• Intervention / Treatment: Other: NP2-4mg; Other: NP2-6 mg; Other: Loz-4mg; Other: Gum-4mg

• Study Type: Interventional
• Enrollment (Actual): 56
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Christelle Haziza, PhD; Phone Number: +41582421111; Email: Christelle.Haziza@pmi.com
• Study Contact Backup: Name: Steffen Fredersdorf, PhD; Phone Number: +41582421111

Study Locations

• Canada
  • Québec, Canada, G1P 0A2
    • Syneos Health Clinique Inc.
  • Ontario
    • Toronto, Ontario, Canada, M1S 3V6
      • Pharma Medica Research Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subject has signed the ICF and is able to understand the information provided in the ICF.
• Subject has smoked on a daily basis for at least the last 18 months prior to the Screening visit.
• Subject has smoked on average ≥10 commercially available regular CIG/day over the last 4 weeks. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
• Subject is healthy as judged by the Investigator based on available assessments from the screening period (e.g., safety laboratory, spirometry, vital signs, physical examination, ECG, and medical history).

Exclusion Criteria:

• Subject has reasons other than medical (e.g., psychological, social reason) not to be part of the study, as determined by the Investigator.
• Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners).
• Subject has a clinically relevant disease which requires medication or any other medical condition including abnormal spirometry, safety laboratory, as determined by the Investigator.
• Subject presents difficulty with venipuncture and/or poor venous access.
• Subject has an oromucosal or dental condition, which may affect the use of the investigational products, as determined by the Investigator or subject has orthodontic braces and retention wire (could likely interfere with the gum dosing).
• Subject has medical conditions which require, or will require during the study, a medical intervention (e.g., start of treatment, surgery, hospitalization).
• Presence of fever (body temperature >37.5°C) (e.g., a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
• Subject has a Hemoglobin level < 11.0 g/dL for females and < 12.0 g/dL for males at the Screening.
• Subject uses medication or any substance that aids in smoking cessation.
• Subject postponed the decision to quit using tobaccoor nicotine-containing products in order to participate in this study.
• Subject previously attempted to quit using tobacco- or nicotine-containing products within 28 days prior to the first study product administration.
• Subject has donated plasma within seven days prior to Screening or has donated or lost 450 mL or more of whole blood within 8 weeks prior to Screening for males, and in the 12 weeks prior to Screening for females.
• Subject has a known sensitivity or allergy to any of the investigational products, or ingredients.
• Subject has a positive serology test for HIV 1/2, Hepatitis B, Hepatitis C.
• Subject has a history of alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
• Subject has a positive urine drug test. Investigator will assess whether THC positive subjects are eligible for participation in the study.
• Subject has a positive alcohol breath test.
• Subject or one of their family members is a current or former employee of the tobacco industry.
• Subject or one of their family members a is an employee of the investigational site or of any other parties involved in the study.
• Subject has participated in another clinical study within 30 days prior to the Screening Visit or concomitantly participates in an investigational study involving no drug or device administration.
• Subject has been previously screened or enrolled in this study (except alternate subjects).
• For women only: subject is pregnant (does not have negative pregnancy tests at Screening Visit and at Admission) or is a lactating female.
• For women of childbearing potential only: subject does not agree to use an acceptable method of effective contraception.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Product Sequence 1; From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg	Other: NP2-4mg; NP2-4 mg is a new product containing tobacco-derived nicotine.; Other: NP2-6 mg; NP2-6 mg is a new product containing tobacco-derived nicotine.; Other: Loz-4mg; The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.; Other: Gum-4mg; The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Active Comparator: Product Sequence 2; From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg	Other: NP2-4mg; NP2-4 mg is a new product containing tobacco-derived nicotine.; Other: NP2-6 mg; NP2-6 mg is a new product containing tobacco-derived nicotine.; Other: Loz-4mg; The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.; Other: Gum-4mg; The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Active Comparator: Product Sequence 3; From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg	Other: NP2-4mg; NP2-4 mg is a new product containing tobacco-derived nicotine.; Other: NP2-6 mg; NP2-6 mg is a new product containing tobacco-derived nicotine.; Other: Loz-4mg; The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.; Other: Gum-4mg; The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Active Comparator: Product Sequence 4; From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg	Other: NP2-4mg; NP2-4 mg is a new product containing tobacco-derived nicotine.; Other: NP2-6 mg; NP2-6 mg is a new product containing tobacco-derived nicotine.; Other: Loz-4mg; The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.; Other: Gum-4mg; The Gum-4mg reference product is a commercially available 4mg nicotine gum.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Plasma Concentration [Cmax]	To measure Cmax following use of the investigational products and reference products	Measured from start of product use to 24 hours
Area under the observed concentration-time curve (AUC) from start of product use (T0) to timepoint of last quantifiable concentration [AUC0-last] and extrapolated to infinity [AUC0-infinity]	To measure the area under the background-corrected concentration-time curve (AUC) from start of product use	Measured from start of product use (T0) to 2 minutes, to 4 minutes, to 10 hours, to time of last quantifiable concentration.
Ratio of [AUC0-last] and [AUC0-infinity]	To measure the ratio of [AUC0-last] and [AUC0-infinity]	Measured from start of product use to 24 hours
Time to the observed maximum concentration [Tmax]	To measure the maximum ratio of background-corrected concentration over time, from T0 (excluded) to Tmax (included)	Measured from start of product use to 24 hours
Elimination rate constant [kel]	To measure the fraction of nicotine eliminated per unit of time, following use of the investigational products and reference products	Measured from start of product use to 24 hours
Half-life of nicotine [t1/2]	To measure the half-life of nicotine, following use of the investigational products and reference products	Measured from start of product use to 24 hours

Collaborators and Investigators

• Sponsor: Philip Morris Products S.A.
• Investigators: Study Chair: Christelle Haziza, PhD, Philip Morris Products S.A.

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2023
• Primary Completion (Actual): January 14, 2024
• Study Completion (Estimated): July 31, 2024

Study Registration Dates

• First Submitted: December 6, 2023
• First Submitted That Met QC Criteria: December 13, 2023
• First Posted (Actual): December 14, 2023

Study Record Updates

• Last Update Posted (Estimated): February 2, 2024
• Last Update Submitted That Met QC Criteria: February 1, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Tobacco; Nicotine; Nicotine-containing products
• Other Study ID Numbers: PZ-PK-03-CAN

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No